to its Current Report on Form 8-K, filed

Catalent, Inc. Announces Pricing of Public Offering of Common Stock

SOMERSET, N.J. July 24, 2018 Catalent, Inc. ( Catalent ) (NYSE:CTLT), the leading global provider of advanced delivery

technologies and development solutions for drugs, biologics and consumer health products, today announced the pricing of an underwritten public offering (the Offering ) of 9,940,358 shares of its common stock at a price to the public of

$40.24 per share. In connection with the Offering, Catalent has granted the underwriters an option for 30 days to purchase up to an additional 1,491,053 shares of its common stock sold at the public offering price, less the underwriting discount.

Subject to customary closing conditions, the Offering is expected to settle and close on or about July 27, 2018.

The net proceeds from the Offering

will be approximately $387.0 million after deducting the underwriting discount and estimated offering expenses, assuming no exercise by the underwriters of their option to purchase additional shares. Catalent intends to use the net proceeds of the

Offering to repay a corresponding portion of the outstanding borrowings under its U.S. dollar-denominated term loans.

J.P. Morgan, Morgan Stanley, RBC

Capital Markets, BofA Merrill Lynch and Wells Fargo Securities are acting as bookrunners for the Offering.

This press release does not constitute an

offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of such shares of common stock or any other security of Catalent in any state or jurisdiction in which such offer, solicitation, or sale

would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The Offering is being made pursuant

to an effective shelf registration statement, including a base prospectus, that was filed with the Securities and Exchange Commission (the SEC ) on June 6, 2016 and is available on the SEC website. A preliminary prospectus supplement

and the accompanying base prospectus related to the Offering have been filed with the SEC on July 23, 2018 and are available on the SEC website. Copies of these documents and the final prospectus supplement, when available, may be obtained from

J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204, or by email at prospectus_eq@jpmchase.com; Morgan

Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; RBC Capital Markets LLC, Attention: Equity Syndicate Department, 200 Vesey Street, 8th Floor, New York, NY 10281; by phone at (877)

822-4089; or by email at equityprospectus@rbccm.com; BofA Merrill Lynch, NC1-004-03-43,

200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, Email: dg.prospectus_requests@baml.com; and Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152,

at (800) 326-5897 or email a request to cmclientsupport@wellsfargo.com. The registration statement is available on the SEC s website at www.sec.gov under Catalent s name.

FORWARD-LOOKING STATEMENTS

This release contains both historical and forward-looking statements, including regarding the expected consummation of the proposed offering and plans and

estimates regarding the use of proceeds therefrom. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and

Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified because they relate to the topics set forth above or by the use of statements that include phrases such as

believe, expect, anticipate, intend, estimate, plan, project, foresee, likely, may, will, would or other

words or phrases with similar meanings. Similarly, statements that describe Catalent s objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying

assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent s expectations and projections. Some of the factors that could cause actual results to differ include, but are not

limited to, the following: participation in a highly competitive market and increased competition may adversely affect Catalent s business; demand for Catalent s offerings which depends in part on their customers research and

development and the clinical and market success of their products; product and other liability risks that could adversely affect Catalent s results of operations, financial condition, liquidity, and cash flows; failure to comply with existing

and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on the business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex

services or support required; global economic, political, and regulatory risks to Catalent s operations; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights,

trademarks, and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products Catalent manufactures, including active pharmaceutical ingredients, excipients, purchased

components, and raw materials; changes in market access or healthcare reimbursement in the United States or internationally; fluctuations in the exchange rate of the U.S. dollar and other foreign currencies including as a result of the recent U.K.

referendum to exit from the European Union; adverse tax legislative or regulatory initiatives or challenges to Catalent s tax positions; loss of key personnel; risks generally associated with information systems; inability to complete any

future acquisitions and other transactions that may complement or expand the business of Catalent or divest of non-strategic businesses or assets and Catalent s ability to successfully integrate acquired

businesses and realize anticipated benefits of such acquisitions; offerings and customers products that may infringe on the intellectual property rights of third parties; environmental, health, and safety laws and regulations, which could

increase costs and restrict operations; labor and employment laws and regulations or labor difficulties, which could increase costs or result in disputes; additional cash contributions required to fund Catalent s existing pension plans;

substantial leverage resulting in the limited ability of Catalent to raise additional capital to fund operations and react to changes in the economy or in the industry; exposure to interest rate risk to the extent of Catalent s variable rate

debt and preventing Catalent from meeting its obligations under its indebtedness. For a more detailed discussion of these and other factors, see the information

under the caption Risk Factors in Catalent s preliminary prospectus supplement filed July 23, 2018 with the SEC, Catalent s Annual Report on Form 10-K for the fiscal year ended June 30, 2017, filed August 28, 2017 with the SEC, Catalent s Quarterly Report on Form 10-Q for the quarter ended

December 31, 2017, filed February 5, 2018 with the SEC, Catalent s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed May 1, 2018 with the SEC, and Exhibit 99.4

to its Current Report on Form 8-K, filed September 25, 2017 with the SEC. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent does not

undertake to update any forward-looking statement as a result of new information or future events or developments except to the extent required by law.

Thomas Castellano, 732-537-6325